Sonnet Biotherapeutics Holdings Inc
SONN
查看详细走势图
1.260USD
0.000
收盘 12/24, 13:00（美东）报价延迟15分钟
4.20M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
0.00%
1月
-74.02%
6月
+10.04%
今年开始到现在
-13.70%
1年
-11.27%
查看详细走势图
TradingKey Sonnet Biotherapeutics Holdings Inc股票评分
单位: USD 更新时间: 2025-12-02操作建议
Sonnet Biotherapeutics Holdings Inc当前公司基本面数据相对非常健康，当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Sonnet Biotherapeutics Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
20.000
目标均价
+1487.30%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Sonnet Biotherapeutics Holdings Inc亮点
亮点风险
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
业绩增长期
公司处于发展阶段，最新年度总收入18.63K美元
估值合理
公司最新PE估值-0.18，处于3年历史合理位
机构减仓
最新机构持股348.20K股，环比减少56.05%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值96.38K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.75
Sonnet Biotherapeutics Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Sonnet Biotherapeutics Holdings Inc简介
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
公司代码SONN
公司Sonnet Biotherapeutics Holdings Inc
CEORao (Raghu)
网址https://www.sonnetbio.com/
常见问题
Sonnet Biotherapeutics Holdings Inc(SONN)的当前股价是多少？
Sonnet Biotherapeutics Holdings Inc(SONN)的当前股价是 1.260。
Sonnet Biotherapeutics Holdings Inc的股票代码是什么？
Sonnet Biotherapeutics Holdings Inc的股票代码是SONN。
Sonnet Biotherapeutics Holdings Inc股票的52周最高点是多少？
Sonnet Biotherapeutics Holdings Inc股票的52周最高点是19.300。
Sonnet Biotherapeutics Holdings Inc股票的52周最低点是多少？
Sonnet Biotherapeutics Holdings Inc股票的52周最低点是1.080。
Sonnet Biotherapeutics Holdings Inc的市值是多少？
Sonnet Biotherapeutics Holdings Inc的市值是4.20M。
Sonnet Biotherapeutics Holdings Inc的净利润是多少？
Sonnet Biotherapeutics Holdings Inc的净利润为-7.44M。
现在Sonnet Biotherapeutics Holdings Inc(SONN)的股票是买入、持有还是卖出？
根据分析师评级，Sonnet Biotherapeutics Holdings Inc(SONN)的总体评级为买入，目标价格为20.000。
Sonnet Biotherapeutics Holdings Inc(SONN)股票的每股收益（EPS TTM）是多少
Sonnet Biotherapeutics Holdings Inc(SONN)股票的每股收益（EPS TTM）是-6.823。
相关品种
